Colorectal Cancer Metastatic clinical trials

Explore recruiting colorectal cancer metastatic clinical trials.

Recruiting colorectal cancer metastatic studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Colorectal Cancer Metastatic trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

PHASE Ib STUDY WITH THE COMBINATION OF LB−100 (PP2A INHIBITOR) AND AZENOSERTIB (WEE1 INHIBITOR) IN PATIENTS WITH METASTATIC COLORECTAL CANCER The COLLEE trial

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

Evaluation of treatment PERSOnalization based on its therapeutic monitoring in patients with metastatic colorectal cancer treated with regorafenib

France

Therapeutic exploratory (Phase II) EU CTIS Study details

To Study the Safety and Pharmacokinetics of BLYG8824A in Patients with Locally Advanced or Metastatic Colorectal Cancers

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Randomized and multicentre Phase II study of FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) alone or in combination with hepatic chemoembolization (Lifepearls-Irinotecan) in patients with colorectal cancer and metastatic disease limited to the liver with bad prognosis.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

An open-label, randomised, phase III study comparing trifluridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy (SOLSTICE study).

Sweden, Slovakia, Poland, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase I/II study with galunisertib combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer with peritoneal metastases

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Colorectal Cancer Metastatic trials by city

Colorectal Cancer Metastatic in Toronto Colorectal Cancer Metastatic in Vancouver Colorectal Cancer Metastatic in Montreal Colorectal Cancer Metastatic in Calgary Colorectal Cancer Metastatic in Edmonton Colorectal Cancer Metastatic in Ottawa Colorectal Cancer Metastatic in Winnipeg Colorectal Cancer Metastatic in Quebec City Colorectal Cancer Metastatic in Hamilton Colorectal Cancer Metastatic in Kitchener Colorectal Cancer Metastatic in London Colorectal Cancer Metastatic in Halifax Colorectal Cancer Metastatic in New York Colorectal Cancer Metastatic in Los Angeles Colorectal Cancer Metastatic in Chicago Colorectal Cancer Metastatic in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease